|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Methylation frequency of CLDN11 (OR, 25.56; 95% CI, 2.32-281.66; p = 0.008), MGMT (OR, 4.64; 95% CI, 1.98-10.90; p = 0.0004), p16 (OR, 4.31; 95% CI, 1.33-13.96; p = 0.01), and RASSF1A (OR, 10.10; 95% CI, 2.87-35.54; p = 0.0003) was significantly higher in metastasis melanoma compared with controls.
|
30370527 |
2019 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clinical and Prognostic Significance of O<sup>6</sup>-Methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Melanoma: A Systematic Meta-Analysis.
|
29606808 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TMZ is in clinical use for melanoma, but objective response rates are low, even when TMZ is combined with O6-benzylguanine (O6BG), a potent MGMT inhibitor.
|
30274152 |
2018 |
|
melanoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Because methylation of MGMT promoter increases the efficacy of alkylating agents, studies on melanoma outcome of patients treated with melphalan regional chemotherapy should consider this epigenetic change.
|
28486243 |
2017 |
|
melanoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Combined treatment with 5-Aza-2'-deoxycytidine and Trichostatin A led to reexpression of MGMT, indicating that DNA methylation and histone deacetylation are associated with silencing of MGMT in melanoma.
|
26943799 |
2016 |
|
melanoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Together, this implies that MGMT promoter methylation is associated with response to single-agent DTIC/TMZ and longer PFS in disseminated cutaneous melanoma.
|
25400033 |
2015 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Western blot analysis demonstrated that 2-day continuous exposure to 40 µM orlistat did not affect MGMT levels in a human melanoma cell line, but downregulated the repair protein by 30-70% in human peripheral blood mononuclear cells, in two leukemia and two colon cancer cell lines.
|
26035182 |
2015 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using multiplex ligation-dependent probe amplification, we identified a deletion that included the MGMT gene in one of 64 families with a melanoma predisposition living in western Sweden.
|
24801985 |
2014 |
|
melanoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT methylation appears to be a late event in the biological history of melanoma and is more frequently seen in visceral metastases.
|
22544212 |
2012 |
|
melanoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
|
22614944 |
2012 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
|
21329652 |
2011 |
|
melanoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.
|
20736948 |
2010 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study we used a human melanoma cell line (GA) and its selected 6-TG drug resistant variant (GA-6-TG) to investigate whether MGMT plays a role in determining the drug resistant phenotype of GA-6-TG cells.
|
19946217 |
2010 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
RGD |
Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
|
20182810 |
2010 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
|
19367283 |
2009 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
We have shown that Ad-IL-24 via exogenous IL-24 protein induces combinatorial synergy of temozolomide-induced cell killing in temozolomide-resistant melanoma cells by inhibition of MGMT.
|
19056673 |
2008 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Biopsies of subcutaneous and lymph node metastases obtained before chemotherapy in 65 patients with disseminated malignant melanoma were examined for MGMT protein levels by immunohistochemistry using a monoclonal anti-human MGMT antibody.
|
12170182 |
2002 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
HPO |
|
|
|